Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617039 | 0.80 | KMT2A (0.54) | KMT2AMEN1GAAL3MBTL1MAPT | |
| SCHEMBL30232579 | 0.80 | KMT2A (0.54) | KMT2AMEN1GAAL3MBTL1MAPT | |
| SCHEMBL820817 | 0.79 | MAPT (0.57) | KMT2AMEN1GAAL3MBTL1MAPT | |
| SCHEMBL14547467 | 0.79 | MAPT (0.57) | KMT2AMEN1GAAL3MBTL1MAPT | |
| SCHEMBL28022704 | 0.78 | MEN1 (0.46) | KMT2AMEN1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL615095 | 0.78 | MAPT (0.46) | KMT2AMEN1GAAL3MBTL1MAPT | |
| SCHEMBL2789512 | 0.78 | KMT2A (0.54) | KMT2AMEN1GAAL3MBTL1MAPT | |
| SCHEMBL9224006 | 0.78 | KMT2A (0.52) | KMT2AMEN1GAAL3MBTL1MAPT | |
| SCHEMBL3687848 | 0.75 | KMT2A (0.40) | KMT2AMEN1GAAL3MBTL1MAPT | |
| Iodide SCHEMBL6674629 | 0.75 | HTR2A (0.53) | KMT2AMEN1GAAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473805-B2 | Process for obtaining tolterodine | RAGACTIVES, S.L. PARQUE TECNOLOGICO DE BOECILLO (ES) | 2009-01-06 | — | — | US | disclosed |
| US-20070254959-A1 | Process for Obtaining Tolterodine | RAGACTIVES, S.L. (ES) | 2007-11-01 | — | — | US | disclosed |
| EP-1698615-B1 | METHOD OF OBTAINING TOLTERODINE | RAGACTIVES SL (ES) | 2007-10-31 | — | — | EP | disclosed |
| EP-1698615-A1 | METHOD OF OBTAINING TOLTERODINE | Ragactives, S.L. (ES) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254959-A1 | Process for Obtaining Tolterodine | ADRB2, ADRB3, ADRB1 | KMT2A 2030/4885MEN1 4353/4885GAA 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.